We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sofosbuvir

News List

U.S. Food and Drug Administration Approves New Formulation of Epclusa, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C firstwordpharma
June 11, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that FDA has approved an expansion of the pediatric indication of Epclusa® for the treatment of chronic hepatitis C virus (HCV) to now include children as young as 3 years of age
Sofosbuvir found to be effective against Zika virus europeanpharmaceuticalreview
April 29, 2019
In both cell cultures and mouse models, sofosbuvir a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus — and blocked transmission of the virus to mouse fetuses.
Sofosbuvir found to be effective against Zika virus europeanpharmaceuticalreview
April 29, 2019
A drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus…
Sofosbuvir can be a potential treatment for patients with Zika virus europeanpharmaceuticalreview
January 29, 2018
A drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus…